New drug could protect Babies' brains after birth complications
NCT ID NCT05778188
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a drug called RLS-0071 in newborns who have brain damage from lack of oxygen during birth. The babies also receive standard cooling therapy. The goal is to see if the drug is safe and may help reduce brain injury. About 70 babies will take part, and they will be followed for up to 2 years.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
RLS-0071 (a peptide drug given by infusion)
What this could lead to
If it works, this could point toward a treatment that reduces brain damage and improves outcomes for newborns with HIE.
What could go wrong
This is an early phase 2 trial with only 70 babies, so results are preliminary. The drug may not prove effective or could have side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPOXIC ISCHEMIC ENCEPHALOPATHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Study Site 001
RECRUITINGGainesville, Florida, 32608, United States
-
Study Site 002
RECRUITINGBoston, Massachusetts, 02115, United States
-
Study Site 003
RECRUITINGDurham, North Carolina, 27710, United States
-
Study Site 005
RECRUITINGMorgantown, West Virginia, 26506, United States
-
Study Site 006
RECRUITINGSt Louis, Missouri, 63110, United States
-
Study Site 010
RECRUITINGOrlando, Florida, 32803, United States
-
Study Site 012
WITHDRAWNLexington, Kentucky, 40536, United States
-
Study Site 013
RECRUITINGOrange, California, 92868, United States
-
Study Site 014
RECRUITINGIndianapolis, Indiana, 46202, United States
-
Study Site 016
RECRUITINGLittle Rock, Arkansas, 72202, United States
-
Study Site 018
RECRUITINGMiami, Florida, 33143, United States
-
Study Site 019
RECRUITINGSan Diego, California, 92123, United States
-
Study Site 020
RECRUITINGSan Diego, California, 92037, United States
-
Study Site 021
RECRUITINGCleveland, Ohio, 44195, United States
-
Study Site 022
RECRUITINGFort Worth, Texas, 76104, United States